ITTO920189A1 - Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico. - Google Patents

Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico.

Info

Publication number: ITTO920189A1
Authority: IT; Italy
Prior art keywords: high purity; industrial scale; therapeutic use; von willebrand; willebrand factor
Prior art date: 1991-03-08

Application number

IT000189A

Other languages

English (en)

Inventor

Thierry Burnouf

Miryana Burnouf-Radosevich

Original Assignee

Ct Regional De Transfusion Sanguine De Lille

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-08

Filing date

1992-03-06

Publication date

1993-09-06

1992-03-06 Application filed by Ct Regional De Transfusion Sanguine De Lille filed Critical Ct Regional De Transfusion Sanguine De Lille

1992-03-06 Publication of ITTO920189A0 publication Critical patent/ITTO920189A0/it

1993-09-06 Publication of ITTO920189A1 publication Critical patent/ITTO920189A1/it

1995-12-12 Application granted granted Critical

1995-12-12 Publication of IT1256692B publication Critical patent/IT1256692B/it

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

ITTO920189A 1991-03-08 1992-03-06 Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico. IT1256692B (it)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9102804A FR2673632A1 (fr)	1991-03-08	1991-03-08	Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique.

Publications (3)

Publication Number	Publication Date
ITTO920189A0 ITTO920189A0 (it)	1992-03-06
ITTO920189A1 true ITTO920189A1 (it)	1993-09-06
IT1256692B IT1256692B (it)	1995-12-12

Family

ID=9410505

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ITTO920189A IT1256692B (it)	1991-03-08	1992-03-06	Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico.

Country Status (29)

Country	Link
US (1)	US5408039A (it)
EP (1)	EP0503991B1 (it)
JP (1)	JP3435668B2 (it)
AT (1)	AT407115B (it)
AU (1)	AU645172B2 (it)
BE (1)	BE1004178A3 (it)
BR (1)	BR9200770A (it)
CA (1)	CA2062340C (it)
CZ (1)	CZ283633B6 (it)
DE (2)	DE122009000034I2 (it)
DK (1)	DK0503991T3 (it)
EE (1)	EE03057B1 (it)
EG (1)	EG20300A (it)
ES (1)	ES2121830T3 (it)
FI (1)	FI106721B (it)
FR (1)	FR2673632A1 (it)
HU (1)	HU215098B (it)
IL (1)	IL101043A (it)
IT (1)	IT1256692B (it)
LT (1)	LT3175B (it)
NL (1)	NL300394I1 (it)
NO (1)	NO301278B1 (it)
NZ (1)	NZ241701A (it)
PL (1)	PL168353B1 (it)
RU (1)	RU2088590C1 (it)
SA (1)	SA92120446B1 (it)
SK (1)	SK279533B6 (it)
UA (1)	UA27732C2 (it)
ZA (1)	ZA921430B (it)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4435485C1 (de) *	1994-10-04	1996-03-21	Immuno Ag	Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
DE4435392B4 (de) *	1994-10-04	2008-02-07	Immuno Ag	Verfahren zur Trennung von vWF in hochmolekularen vWF und niedermolekularen vWF
DE4437544A1 (de) *	1994-10-20	1996-04-25	Behringwerke Ag	Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5659017A (en) *	1995-11-07	1997-08-19	Alpha Therapeutic Corporation	Anion exchange process for the purification of Factor VIII
US6005077A (en) *	1995-11-10	1999-12-21	Immuno Aktiengesellschaft	Use of von willebrand factor and pharmaceutical formulation
DE19616540A1 (de) *	1995-11-10	1997-05-15	Immuno Ag	Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
AT403764B (de)	1996-03-15	1998-05-25	Immuno Ag	Stabiler faktor viii/vwf-komplex
US6068838A (en) *	1996-04-29	2000-05-30	Baxter Aktiengesellschaft	Purified multimerase
AT404358B (de) *	1997-02-04	1998-11-25	Immuno Ag	Verfahren zur chromatographischen reinigung bzw. fraktionierung von von willebrand-faktor aus einem vwf-hältigen ausgangsmaterial
AT405403B (de)	1997-02-27	1999-08-25	Immuno Ag	Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
AT405485B (de) *	1997-05-28	1999-08-25	Immuno Ag	Eine das vwf-propeptid enthaltende pharmazeutische präparation
EP2130554B1 (en)	1999-02-22	2012-09-05	University of Connecticut	Albumin-free factor VIII formulations
EP1148063A1 (de) *	2000-04-18	2001-10-24	Octapharma AG	Haemostatisch aktives vWF enthaltendes Präparat und Verfahren zu seiner Herstellung
RU2200028C2 (ru) *	2000-06-20	2003-03-10	Кировский НИИ гематологии и переливания крови	Способ пломбировки пункционного канала после диагностической эндоскопической пункционной биопсии печени у больных гемофилией а
EP1593388A1 (en) *	2004-05-05	2005-11-09	ZLB Behring GmbH	Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
FR2874216B1 (fr) *	2004-08-16	2006-11-03	Lab Francais Du Fractionnement	Procede de preparation d'un concentre de facteur von willebrand (fvw) par voie chromatographique et concentre de fvw susceptible d'etre ainsi obtenu
DE102004044419B4 (de)	2004-09-14	2010-04-15	Biotest Ag	Verfahren zur Aufreinigung eines von Willebrand Faktors mittels Hydroxylapatit-Durchlaufchromatographie
DE102004044429B4 (de) *	2004-09-14	2009-04-30	Biotest Ag	Verfahren zur Herstellung einer Zusammensetzung enthaltend von Willebrand Faktor
ITLU20070007A1 (it) *	2007-05-07	2008-11-08	Kedrion Spa	Processo cromatografico per l'ottenimento di un complesso fviii/vwf con differenti rapporti tra le due proteine da utilizzare nella terapia della emofilia a e nella malattia di von willebrand.
KR20100019999A (ko)	2007-06-13	2010-02-19	체에스엘 베링 게엠베하	출혈 장애의 치료법 및 예방 처치에 있어서의 혈관외 투여용 ｖｗｆ 안정화된 ｆｖｉｉｉ 제제 및 ｆｖｉｉｉ 무함유 ｖｗｆ 제제의 용도
FR2920429B1 (fr) *	2007-08-30	2012-10-05	Lfb Biotechnologies	Procede de purification du facteur viii et du facteur von willebrand
US20100273206A1 (en) *	2007-12-21	2010-10-28	Manfred Rauh	Diagnostic in vitro method for assessing von willebrand disease and increased bleeding risk associated with von willebrand disease and acquired or congenital disorders of platelet function
EP2073015A1 (en)	2007-12-21	2009-06-24	CSL Behring GmbH	Diagnostic in vitro method for assessing Von Willebrand Disease and bleeding risk associated with Von Willebrand Disease and acquired or congenital disorders of platelet function
EP2291523B1 (en)	2008-06-24	2014-12-17	CSL Behring GmbH	Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
BRPI0921429B1 (pt)	2008-11-07	2022-07-12	Takeda Pharmaceutical Company Limited	Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável
IT1396528B1 (it)	2009-01-19	2012-12-14	Kedrion Spa	Nuovo processo di purificazione altamente selettivo di due proteine plasmatiche: von willebrand factor (vwf) e fibronectina (fn).
CN102470182A (zh)	2009-08-20	2012-05-23	德国杰特贝林生物制品有限公司	用于在出血性紊乱的治疗和预防性处理中进行非静脉内施用的白蛋白融合凝血因子
AU2011343813B2 (en)	2010-12-15	2015-05-21	Takeda Pharmaceutical Company Limited	Eluate collection using conductivity gradient
CN103889445A (zh)	2011-10-18	2014-06-25	德国杰特贝林生物制品有限公司	硫酸化糖胺聚糖用于改善因子viii的生物利用度的用途
JP6029674B2 (ja)	2011-10-18	2016-11-24	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用
US9458223B2 (en)	2012-02-15	2016-10-04	Csl Behring Gmbh	Von willebrand factor variants having improved factor VIII binding affinity
DK2796145T3 (da)	2013-04-22	2018-01-29	Csl Ltd	Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
ES2693380T3 (es)	2013-11-08	2018-12-11	Csl Limited	Nuevo método para concentrar el factor de von Willebrand o complejos de este
KR20170026580A (ko)	2014-07-02	2017-03-08	씨에스엘 리미티드	변형된 폰 빌레브란트 인자
US10626164B2 (en)	2014-07-25	2020-04-21	Csl Limited	Purification of VWF
FR3034669B1 (fr)	2015-04-07	2020-02-14	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Nouvelle utilisation du facteur von willebrand
EP3362464B1 (en) *	2015-10-15	2021-04-28	Plasma Technologies LLC	Methods for extracting proteins from blood plasma
KR20180094114A (ko)	2016-01-07	2018-08-22	체에스엘 베링 리컴비넌트 퍼실리티 아게	돌연변이된 절단된 폰 빌레브란트 인자
CA3008448A1 (en)	2016-01-07	2017-07-13	Csl Behring Recombinant Facility Ag	Mutated von willebrand factor
CN105541997A (zh) *	2016-02-04	2016-05-04	江西博雅生物制药股份有限公司	一种高纯度和高活性血管性血友病因子的制备工艺
CN105622747A (zh) *	2016-02-04	2016-06-01	江西博雅生物制药股份有限公司	一种vWF活性保护液
CN105622746A (zh) *	2016-02-04	2016-06-01	江西博雅生物制药股份有限公司	一种从冷沉淀提取凝血因子ⅷ的废料中提取人血管性血友病因子的制备工艺
EP3488858A1 (en)	2017-11-27	2019-05-29	Laboratoire Français du Fractionnement et des Biotechnologies	A von willebrand factor composition for use in treating a pathology mediated by angiogenesis
CN114249812B (zh) *	2020-09-22	2023-09-15	四川远大蜀阳药业有限责任公司	一种降低vWF制品中IgM含量的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61166542A (ja) *	1985-01-18	1986-07-28	Hitachi Chem Co Ltd	感光性組成物
US4970300A (en) *	1985-02-01	1990-11-13	New York University	Modified factor VIII
US5006642A (en) *	1987-06-29	1991-04-09	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Purification of von Willebrand Factor by affinity chromatography
FR2632309B1 (fr) *	1988-06-07	1990-08-24	Lille Transfusion Sanguine	Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus

1991
- 1991-03-08 FR FR9102804A patent/FR2673632A1/fr active Granted
1992
- 1992-02-19 AU AU11131/92A patent/AU645172B2/en not_active Expired
- 1992-02-24 IL IL10104392A patent/IL101043A/xx not_active IP Right Cessation
- 1992-02-24 NZ NZ241701A patent/NZ241701A/en not_active IP Right Cessation
- 1992-02-26 CZ CS92568A patent/CZ283633B6/cs not_active IP Right Cessation
- 1992-02-26 SK SK568-92A patent/SK279533B6/sk not_active IP Right Cessation
- 1992-02-26 ZA ZA921430A patent/ZA921430B/xx unknown
- 1992-02-27 DE DE122009000034C patent/DE122009000034I2/de active Active
- 1992-02-27 EP EP92400505A patent/EP0503991B1/fr not_active Expired - Lifetime
- 1992-02-27 DE DE69227055T patent/DE69227055T2/de not_active Expired - Lifetime
- 1992-02-27 DK DK92400505T patent/DK0503991T3/da active
- 1992-02-27 ES ES92400505T patent/ES2121830T3/es not_active Expired - Lifetime
- 1992-03-03 JP JP08030592A patent/JP3435668B2/ja not_active Expired - Lifetime
- 1992-03-04 BE BE9200215A patent/BE1004178A3/fr not_active IP Right Cessation
- 1992-03-05 CA CA002062340A patent/CA2062340C/fr not_active Expired - Lifetime
- 1992-03-05 NO NO920867A patent/NO301278B1/no not_active IP Right Cessation
- 1992-03-06 US US07/846,852 patent/US5408039A/en not_active Expired - Lifetime
- 1992-03-06 PL PL92293738A patent/PL168353B1/pl unknown
- 1992-03-06 AT AT0043692A patent/AT407115B/de not_active IP Right Cessation
- 1992-03-06 RU SU925011041A patent/RU2088590C1/ru active
- 1992-03-06 BR BR929200770A patent/BR9200770A/pt not_active Application Discontinuation
- 1992-03-06 HU HU9200767A patent/HU215098B/hu not_active IP Right Cessation
- 1992-03-06 IT ITTO920189A patent/IT1256692B/it active IP Right Grant
- 1992-03-06 FI FI920992A patent/FI106721B/fi active
- 1992-03-07 EG EG13192A patent/EG20300A/xx active
- 1992-04-18 SA SA92120446A patent/SA92120446B1/ar unknown
- 1992-12-30 LT LTIP266A patent/LT3175B/lt not_active IP Right Cessation
1993
- 1993-05-21 UA UA93002713A patent/UA27732C2/uk unknown
1994
- 1994-05-23 EE EE9400004A patent/EE03057B1/xx not_active IP Right Cessation
2009
- 2009-07-07 NL NL300394C patent/NL300394I1/nl unknown

Also Published As

Publication number	Publication date
CS56892A3 (en)	1992-09-16
ZA921430B (en)	1992-11-25
IT1256692B (it)	1995-12-12
LT3175B (en)	1995-02-27
FI920992A0 (fi)	1992-03-06
HU9200767D0 (en)	1992-05-28
ES2121830T3 (es)	1998-12-16
ITTO920189A0 (it)	1992-03-06
EG20300A (fr)	1998-10-31
NZ241701A (en)	1994-10-26
CA2062340C (fr)	2000-05-09
AU1113192A (en)	1992-09-10
SK279533B6 (sk)	1998-12-02
NL300394I1 (nl)	2009-09-01
RU2088590C1 (ru)	1997-08-27
IL101043A (en)	1997-02-18
LTIP266A (en)	1994-07-15
EE03057B1 (et)	1997-12-15
DE122009000034I2 (de)	2011-06-16
JP3435668B2 (ja)	2003-08-11
UA27732C2 (uk)	2000-10-16
IL101043A0 (en)	1992-11-15
BR9200770A (pt)	1992-11-17
PL168353B1 (pl)	1996-02-29
NO920867D0 (no)	1992-03-05
HUT63176A (en)	1993-07-28
AT407115B (de)	2000-12-27
HU215098B (hu)	1998-09-28
SA92120446B1 (ar)	2004-05-04
CA2062340A1 (fr)	1992-09-09
CZ283633B6 (cs)	1998-05-13
FR2673632B1 (it)	1995-05-05
AU645172B2 (en)	1994-01-06
EP0503991A1 (fr)	1992-09-16
DE122009000034I1 (de)	2010-04-08
FI106721B (fi)	2001-03-30
DE69227055T2 (de)	1999-04-22
FR2673632A1 (fr)	1992-09-11
ATA43692A (de)	2000-05-15
DE69227055D1 (de)	1998-10-29
JPH0597696A (ja)	1993-04-20
PL293738A1 (en)	1992-09-21
DK0503991T3 (da)	1999-06-14
FI920992L (fi)	1992-09-09
NO920867L (no)	1992-09-09
BE1004178A3 (fr)	1992-10-06
EP0503991B1 (fr)	1998-09-23
US5408039A (en)	1995-04-18
NO301278B1 (no)	1997-10-06

Publication	Publication Date	Title
ITTO920189A1 (it)	1993-09-06	Procedimento di preparazione su scala industriale di un concentrato standardizzato di fattore von willebrand umano di altissima purezza ed adatto ad uso terapeutico.
DK272389D0 (da)	1989-06-02	Anvendelse af gamma-hydroxysmoersyresalte til fremstilling af farmaceutiske praeparater til behandling af alkoholisme og praeparater opnaaet herved
IT8603530A0 (it)	1986-09-30	Membrana per uso farmaceutico ed industriale
FI922785A7 (fi)	1992-12-29	Terapeuttisia valmisteita
NO921012D0 (no)	1992-03-16	Farmasoeytiske preparater og deres anvendelse
FI935071A7 (fi)	1993-11-16	Uudet perhydroisoindolit, niiden valmistus ja niitä sisältävät farmase uttiset valmisteet
EP0550807A3 (en)	1993-08-25	Use of preparations of curcuma plants
EP0200508A3 (en)	1987-07-08	Adhesive oral bandages and oral pharmaceutical preparations
ZA935697B (en)	1994-03-10	Peptides capable of inhibiting the activity of hiv protease their preparation and their therapeutic use
DK19893D0 (da)	1993-02-23	Praeparat til nasal behandling
EE9400183A (et)	1995-12-15	Inimese immuunpuudulikkuse viiruse vaktsiin ja kasutamine
DE3682229D1 (de)	1991-12-05	Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
GB9226832D0 (en)	1993-02-17	Pharmaceutical preparations for the treatment of psoriasis
FI934228L (fi)	1993-09-27	Tvaerbindande medel
FI864164A7 (fi)	1987-04-18	Ihmis- -interferonin biologisesti aktiivisia johdoksia, niiden valmistus ja tällaisia johdoksia sisältävlääkkeitä.
DK496889D0 (da)	1989-10-06	Peptidholdigt farmaceutisk praeparat
EP0223254A3 (en)	1989-01-25	Preparations for the treatment and prevention of epithelial destruction
DK590987A (da)	1988-05-13	Peptid og farmaceutisk praeparat indeholdende et saadant peptid
FI923662L (fi)	1993-02-16	Terapeutiska medel
GB2194533B (en)	1990-08-22	Dichlorotrifluoromethyl nitrotoluenes and pharmaceutical and herbicidal amino derivatives thereof
FI940717A7 (fi)	1994-08-18	Streptogramiinien puhdistetut muodot, niiden valmistus ja niitä sisältävät farmaseuttiset valmisteet
IL102540A0 (en)	1993-01-14	Proteins capable of combating plant pathogens,their preparation and their use
IT1228560B (it)	1991-06-21	Procedimento per la preparazione su scala industriale di interferon di leucocita umano ad alta purezza e terapeuticamente utile.
DE58902777D1 (de)	1992-12-24	Herrichtung und verwendung eines physiologisch aktiven polypeptids zur aids-therapie.
DE68914544D1 (de)	1994-05-19	Peptid und Wirkstoff gegen Dementia.

Legal Events

Date	Code	Title	Description
1995-12-12	0001	Granted
1999-10-27	TA	Fee payment date (situation as of event date), data collected since 19931001	Effective date: 19990331